In addition, patients who had progressed to cancer also expressed weaker epithelial cytoplasmic HMGB1 in their background BO (absent + weak intensity in 67%) compared with patients who did not have malignancy (absent + weak intensity in 24%), p = 0.015. Here, HMGB1 is linked to cancer.